Instrument Inactif

Autres langues BioAlliance Pharma SA Euronext Paris

Actions

C4X

Cours en clôture Euronext Paris Autres places de cotation
- ^EUR	-

05/04	Valerio Therapeutics : plus forte baisse du marché SRD à la clôture du vendredi 5 avril 2024	AO
05/04	Valerio Therapeutics : plus forte baisse du marché SRD à la mi-séance du vendredi 5 avril 2024	AO

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Las baratijas de MarketScreener: LVMH, el verdadero precio de las cosas buenas	11/10/23
Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	28/09/23
Onxeo : changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023	06/06/23
Onxeo SA has Changed its Name to Valerio Therapeutics	06/06/23
Biophytis' Finance Chief Resigns; Onxeo Exec Named Successor	02/05/23
Onxeo SA Reports Earnings Results for the Full Year Ended December 31, 2022	29/04/23
Onxeo: Publication of the 2022 Annual Financial Report	28/04/23
Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates	24/04/23
Onxeo will publish its full-year results on April 24, 2023	21/04/23
Bolsa de Madrid: Todavía muchos precios	14/04/23
Onxeo : le titre grimpe après un point sur le développement	26/01/23
Onxeo SA Provides Update on the Development Program For Drug Candidate AsiDNATM	25/01/23
Onxeo : Terms of availability of the preparatory documents for the GM	18/01/23
Half-year liquidity contract statement for ONXEO	04/01/23
Onxeo SA Advances Its Second Lead Candidate Ox425 for the Treatment of Solid Tumors	30/11/22
Bolsa de Madrid: Don't fight the Fed	14/09/22
Onxeo : Inside Information / News release on accounts, results	13/09/22
Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities	13/09/22
Onxeo SA Reports Earnings Results for the Half Year Ended June 30, 2022	13/09/22
High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie	01/09/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BioAlliance Pharma SA Euronext Paris

Actions

C4X

Autres langues

Filtres